Allogene Historical Financial Ratios
| ALLO Stock | USD 2.05 0.13 5.96% |
Allogene Therapeutics is presently reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.93 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Allogene Therapeutics financial condition quickly.
Allogene |
About Allogene Financial Ratios Analysis
Allogene TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Allogene Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Allogene financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Allogene Therapeutics history.
Allogene Therapeutics Financial Ratios Chart
Add Fundamental
Dividend Yield
Dividend Yield is Allogene Therapeutics dividend as a percentage of Allogene Therapeutics stock price. Allogene Therapeutics dividend yield is a measure of Allogene Therapeutics stock productivity, which can be interpreted as interest rate earned on an Allogene Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Return On Tangible Assets
A profitability metric that measures a company's ability to generate earnings from its tangible assets.Most ratios from Allogene Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.At this time, Allogene Therapeutics' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 10th of March 2025, Research And Ddevelopement To Revenue is likely to grow to 2,416, while Price To Sales Ratio is likely to drop 2,416.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.66 | 0.61 | 0.7 | 0.74 | Revenue Per Share | 0.001698 | 6.05E-4 | 6.96E-4 | 6.61E-4 |
Allogene Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Allogene Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.